Disseminated gonococcal infection and eculizumab-A "high risk" connection?

Sexually Transmitted Diseases

Volumn 41, Issue 12, 2014, Pages 747-748

  Hublikar, Siddharth ^a   Maher, William E ^a   Bazan, Jose A ^a,b  

^a THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b Sexual Health Program   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTRIAXONE; ECULIZUMAB; MENINGOCOCCUS VACCINE; VANCOMYCIN; ANTIINFECTIVE AGENT; AZITHROMYCIN; MONOCLONAL ANTIBODY;

ADULT; ARTICLE; BLOOD CULTURE; CASE REPORT; CEREBROSPINAL FLUID ANALYSIS; CHILL; DISSEMINATED GONOCOCCAL INFECTION; FEMALE; FEVER; FOLLOW UP; GONORRHEA; HEADACHE; HUMAN; LUMBAR PUNCTURE; NEISSERIA GONORRHOEAE; NUCLEIC ACID AMPLIFICATION; PAROXYSMAL NOCTURNAL HEMOGLOBINURIA; PHYSICAL EXAMINATION; TRANSTHORACIC ECHOCARDIOGRAPHY; DIRECTIVE COUNSELING; HEMOGLOBINURIA, PAROXYSMAL; IMMUNOLOGY; ISOLATION AND PURIFICATION; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

ADULT; ANTI-BACTERIAL AGENTS; ANTIBODIES, MONOCLONAL, HUMANIZED; AZITHROMYCIN; CEFTRIAXONE; DIRECTIVE COUNSELING; FEMALE; GONORRHEA; HEMOGLOBINURIA, PAROXYSMAL; HUMANS; NEISSERIA GONORRHOEAE; SEXUAL BEHAVIOR; TREATMENT OUTCOME;

EID: 84925878488     PISSN: 01485717     EISSN: 15374521     Source Type: Journal    
DOI: 10.1097/OLQ.0000000000000202     Document Type: Article

References (13)

1. Rice PA. Gonococcal arthritis (disseminated gonococcal infection). Infect Dis Clin North Am. 2005;19:853-861.
2. Tikly M, Diese M, Zannettou N, et al. Gonococcal endocarditis in a patient with systemic lupus erythematosus. Br J Rheumatol. 1997; 36:270-272.
3. Martín MC, Pérez F, Moreno A, et al. Neisseria gonorrhoeae meningitis in pregnant adolescent. Emerg Infect Dis. 2008;14:1672-1674.
4. Thiery G, Tankovic J, Brun-Buisson C, et al. Gonococcemia associated with fatal septic shock. Clin Infect Dis. 2001;32:e92-e93.
5. Del Rio C, Stephens DS, Knapp JS, et al. Comparison of isolates of Neisseria gonorrhoeae causing meningitis and report of gonococcal meningitis in a patient with C8 deficiency. J Clin Micro. 1989;27: 1045-1049.
6. Ross S, Densen P. Complement deficiency states and infection: Epidemiology, pathogenesis and consequences of Neisserial and other infections in an immune deficiency. Medicine (Baltimore). 1984;63:243-273.
7. Ram S, Lewis LA, Rice PA. Infections of people with complement deficiencies and patients who have undergone splenectomy. Clin Microbiol Rev. 2010;23:740-780.
8. Alexion Pharmaceuticals, Inc., Package Insert: Soliris® (eculizumab). Cheshire, CT; 2014. Available at: http://soliris.net/sites/default/files/assets/soliris-pi.pdf. Accessed June 5, 2014.
9. U.S. Food and Drug Administration (FDA). Eculizumab; 2007. Available at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm129251.htm. Accessed June 5, 2014.
10. U.S. Food and Drug Administration (FDA). Eculizumab (Soliris); 2011. Available at: http://www.fda.gov/aboutfda/centersoffices/officeofmedicalproductsandtobacco/cder/ucm273089.htm. Accessed June 5, 2014.
11. Brodsky RA, Young NS, Antonioli E, et al. Multicenter phase 3 study of the complement inhibitor eculizumab for the treatment of patients with paroxysmal nocturnal hemoglobinuria. Blood. 2008; 111:1840-1847.
12. Bleich AT, Sheffield JS, Wendel GD Jr, et al. Disseminated gonococcal infection in women. Obstet Gynecol. 2012;119:597-602.
13. Gleesing J, Chiwane S, Rongkavilit C. Gonococcal septic shock associated with eculizumab treatment. Pediatr Infect Dis J. 2012;31:543.